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Abstract
Hearing loss (HL) is a common condition with both genetic and environmental causes, and it greatly impacts
global health. The prevalence of HL is reportedly higher in developing countries such as the Sub-Saharan
African island of Sa˜o Tome´ and Prı´ncipe, where the deaf community is estimated to be less than 1% of the
population. We investigated the role of the DFNB1 locus (GJB2 and GJB6 genes) in the etiology of non-
syndromic sensorineural hearing loss (NSSHL) in Sa˜o Tome´ and Prı´ncipe. A sample of 316 individuals,
comprising 136 NSSHL patients (92 bilateral, 44 unilateral) and 180 controls, underwent a clinical and au-
diological examination. Sequencing of the GJB2 coding region and testing for the (GJB6-D13S1830) and
del(GJB6-D13S1854) GJB6 deletions were performed. A total of 311 out of 316 individuals were successfully
analyzed regarding the GJB2 and GJB6 genetic variations, respectively. The frequency of the GJB2 coding
mutations in patients and controls was low. Some of those coding mutations are the most commonly found in
Eurasian and Mediterranean populations and have also been identified in Portugal. None of the GJB6 deletions
was present. The presence of certain coding variants in Sa˜o Tome´ and Prı´ncipe suggests a non–Sub-Saharan
genetic influx and supports the previously reported genetic influx from European (mainly Portuguese) ancestors.
In summary, DFNB1 locus does not appear to be a major contributor to NSSHL in Sa˜o Tome´ and Prı´ncipe.
However, the presence of both pathogenic and likely pathogenic mutations in GJB2 suggests that GJB2-related
NSSHL might still occur in this population, warranting further research on GJB2 testing in NSSHL cases.
Introduction
Hearing loss (HL) is a condition that is an outcomeof both environmental and genetic factors. The preva-
lence of HL is higher in certain developing countries such as
many African countries. In Sa˜o Tome´ and Prı´ncipe, the deaf
community is estimated to comprise less than 1% of the
population based on the National Institute of Statistic of Sa˜o
Tome´ and Prı´ncipe (INE, 2014). Mutations in the GJB2 gene
(encoding connexin 26) are responsible for a significant
proportion of nonsyndromic hearing loss (NSHL) cases in
several populations. Two large deletions, del(GJB6-D13S1830)
and del(GJB6-D13S1854), truncating the GJB6 gene (en-
coding connexin 30), are also responsible for NSHL in some
populations, being mostly found in trans with GJB2 muta-
tions (del Castillo et al., 2003, 2005). These genes map to
13q11-q12, and both of them are located within the DFNB1
locus, with the first locus defined for nonsyndromic autoso-
mal recessive HL. Loci for nonsyndromic autosomal reces-
sive HL are designated by DFNB followed by a suffix integer
(Smith and Van Camp, 1998). Mutations in GJB2 reportedly
do not play a significant role in the etiology of HL in Sub-
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Saharan African populations or their descendant populations
(Bosch et al., 2014b; Javidnia et al., 2014; Lasisi et al., 2014;
Shan et al., 2010). The role of del(GJB6-D13S1830) GJB6
large deletion in NSHL in these populations is so far null
(Bosch et al., 2014a; Kabahuma et al., 2011; Samanich et al.,
2007; Shan et al., 2010). Regarding the del(GJB6-D13S1854)
GJB6 deletion, its presence has been investigated in Nigerian
HL patients (Lasisi et al., 2014) and in HL patients of a pre-
dominantly Caribbean Hispanic and African descent (Shan
et al., 2010), without positive results.
Sa˜o Tome´ and Prı´ncipe, a former Portuguese colony, was
formerly settled first by people from different regions of Sub-
Saharan Africa, mostly slaves from the Gulf of Guinea, Congo,
and Angola, brought to work in local plantations, and, to a minor
extent, Portuguese who were involved in the slave trade be-
tween Africa and the Americas. In the first centuries after the
discovery of Sa˜o Tome´ and Prı´ncipe, besides the Portuguese,
other Europeans were involved in the slave trade along the coast
of Africa, namely the French, Spanish, Dutch, and English
(Neves, 1989). In fact, Sa˜o Tome´ and Prı´ncipe’s population has
been shown to present 10.7%– 0.9% of European (mainly
Portuguese) admixture (Toma´s et al., 2002). Therefore, a pu-
tative role of GJB2, or even of the del(GJB6-D13S1830) and
del(GJB6-D13S1854) largeGJB6 deletions, in the HL observed
in Sa˜o Tome´ and Prı´ncipe might potentially be anticipated.
The aim of the present study was to examine the genetic
basis of HL in this understudied Sub-Saharan African island
population, and so as to obtain a broader insight on the role of
genetic contributions to this important disease impacting
global health.
Methods and Materials
Subjects
A total of 316 individuals (136 HL patients and 180 controls),
all of whom were born in Sa˜o Tome´ and Prı´ncipe, ranging from
2 to 35 years old, participated in this study. The subjects were
recruited during consultation provided by the humanitarian
missions in Sa˜o Tome´ and Prı´ncipe, at hospitals, schools, and a
hotel, over a period from February 2012 to May 2014, consti-
tuting a convenience sample. All patients and controls answered
a clinical questionnaire identifying risk factors (family history
of HL, consanguinity, malaria infection, prenatal and perinatal
history, and history of other infections), clinical history, and
otolaryngology observation.
The patients presented with mild to profound nonsyndro-
mic sensorineural hearing loss (NSSHL), which was bilateral
HL in 92 individuals and unilateral HL in 44 individuals. All
the control individuals had normal hearing in both ears. The
patients and control samples did not display a significant
difference in gender ( p = 0.233) and age ( p = 0.271).
The classification of HL was adopted from the World
Health Organization (WHO, 2013). It considers the mean
value of hearing threshold (considering the 0.5, 1, 2, and
4 kHz frequencies) in the better ear. The individual has HL
when the best ear presents a hearing threshold higher than 25
dB and is graded after that with mild (26–40 dB), moderate
(41–60 dB), severe (61–80 dB), and profound (81 dB or
greater) (WHO, 2013).
The project was reviewed and approved by the Medical
Ethics Committee of Sa˜o Tome´ and Prı´ncipe and the Ethics
Research Committee NMSjUNL (n02/2014/CEFCM).
Audiological examination
All 316 individuals were evaluated regarding their hearing
status with a pure tone audiogram—Madsen Midimate 622 or
auditory brainstem response—Vivosonic Integrity V500 au-
diometer depending on collaboration. The audiometric exams
were carried out without an audiometric cabin, with earphones
TDH39, in a closed room, with a level of noise measured
by iPhone de SchabelDoesIT GbR, Munich, Germany (version
1.0.0), considered acceptable, based on ANSI S3.1-1999
(R2013). Electrophysiological thresholds were translated into
the audiometric thresholds for frequencies 2 and 4 kHz, without
applying any correction factor (Gorga et al., 1985, 2006; Jerger
and Mauldin, 1978; van de Drift et al., 1987).
DFNB1 molecular analysis
Peripheral blood samples were collected in Guthrie paper
cards after informed consent had been signed. Approval of
the Medical Ethics Committee was also obtained. Genomic
DNA was extracted from each blood sample by using a
commercially available kit (QIAamp DNA micro kit; Qia-
gen) according to the manufacturer’s instructions. All DNA
samples were stored at -20C until analysis.
Of the 316 subjects, 311 were successfully analyzed by se-
quencing regarding the GJB2 coding region, and by multiplex
polymerase chain reaction (PCR) (del Castillo et al., 2005)
regarding the presence of the two GJB6 large deletions,
del(GJB6-D13S1830) and del(GJB6-D13S1854). These 311
individuals comprise 134 patients (90 bilateral and 44 unilat-
eral) and 177 controls, matched by sex and age. PCR amplifi-
cation and sequencing of the coding region of the GJB2 gene
was performed using previously described primers (Matos
et al., 2010). The GJB2 fragment that was amplified comprises
the coding region and flanking noncoding regions, including
the acceptor splice site. However, the extension of the sequence
obtained beyond the coding region was variable, not allowing
results from the acceptor splice site for all the subjects.
All electrophoretograms were visually inspected; the low-
quality extremities were trimmed off; and heterozygosities
were marked, using the Chromas Lite software (v.2.01). The
resulting analyzed and edited sequences were copied from
Chromas Lite in Fasta format and blasted against the refer-
ence sequence NG_008358.1 using NCBI’s Blast program
(suite 2-sequences). All the variants described here were
named according to the recommendations of the Human
Genome Variation Society.
Statistical analyses
A chi-square test was performed, and p-values were calcu-
lated using the SPSS v.20 software. When chi-square was not
possible, we adopted Fisher’s exact test. Hardy–Weinberg
equilibrium test was performed using Court Lab’s HW calcu-
lator. This test was only performed for c.*84T>C, c.*104A>T,
and c.*111C>T, since these were the only variants whose re-
spective genotypes were all observed in five or more individuals.
Results
Insofar as the GJB2 sequencing is concerned, all the ana-
lyzed subjects were sequenced between c.-2 and c.*6 positions,
although most sequences extended, with quality, several nu-
cleotides before c.-2 and after c.*6. The sequencing results
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allowed for the identification of eight coding variants (Table 1)
and 10 noncoding variants (Table 2) in patients and/or controls.
Coding variants of GJB2
Eight different coding variants, all in heterozygosity, have
been identified in this study, in patients and/or control indi-
viduals (Table 1). None of these patients harbored any mu-
tation in the acceptor splice site.
Noncoding variants of GJB2
We have identified 10 noncoding variants in the subjects of
this study, being the genotyping results presented in Table 2.
The most commonly identified variant in bilateral and uni-
lateral HL patients and controls was c.*84T>C, presenting in
the latter group an allelic frequency of 51.36%. This variant
as well as c.*104A>T and c.*111C>T are in Hardy–
Weinberg equilibrium in the control group.
Table 1. GJB2 Coding Variants Identified in Patients and Controls (All in Heterozygosity)
and Respective Carrier Frequencies
GJB2 coding variants Bilateral HL Unilateral HL Controls
c.35delG (p.Gly12Valfs) 0/90 0/44 1/177 (0.28%)
c.101T>C (p.Met34Thr) 1/90 (0.56%) 0/44 0/177
c.109G>A (p.Val37Ile) 0/90 0/44 1/177 (0.28%)
c.186C>T (p.Asn62 = ) 0/90 0/44 1/177 (0.28%)
c.225G>T (p.Arg75 = ) 1/90 (0.56%) 0/44 5/177 (1.41%)
c.380G>A (p.Arg127His) 1/90 (0.56%) 0/44 1/177 (0.28%)
c.457G>A (p.Val153Ile) 0/90 0/44 1/177 (0.28%)
c.499G>A (p.Val167Met) 1/90 (0.56%) 1/44 (1.14%) 1/177 (0.28%)
Frequency of mutated alleles 4/180 (2.22%) 1/88 (1.13%) 11/354 (3.11%)
HL, hearing loss.
Boldface = carrier frequencies > 0.
Table 2. GJB2 Noncoding Variants Identified in the Subjects and Respective Genotypic Frequencies
GJB2 noncoding
variants Genotypes Bilateral HL Unilateral HL Controls
c.-22-12C>T CC 59.4% (19/32) 60% (6/10) 66.7% (26/39)
CT 31.3% (10/32) 40% (4/10) 30.8% (12/39)
TT 9.4% (3/32) 0% (0/10) 2.6% (1/39)
c.-15C>T CC 82.7% (67/81) 85.7 (36/42) 88% (146/166)
CT 16% (13/81) 14.3% (6/42) 11.4% (19/166)
TT 1.2% (1/81) 0% (0/42) 0.6% (1/166)
c.-14G>A GG 98.8% (80/81) 100% (43/43) 99.4% (165/166)
GA 1.2% (1/81) 0% (0/43) 0.6% (1/166)
AA 0% (0/81) 0% (0/43) 0% (0/166)
c.-7G>A GG 100% (88/88) 100% (44/44) 99.4% (175/176)
GA 0% (0/88) 0% (0/44) 0.6% (1/176)
AA 0% (0/88) 0% (0/44) 0% (0/176)
c.-6T>A TT 100% (89/89) 100% (44/44) 97.7% (172/176)
TA 0% (0/89) 0% (0/44) 2.3% (4/176)
AA 0% (0/89) 0% (0/44) 0% (0/176)
c.*78A>T AA 97.6% (80/82) 100% (40/40) 100% (152/152)
AT 2.4% (2/82) 0% (0/40) 0% (0/152)
TT 0% (0/82) 0% (0/40) 0% (0/152)
c.*84T>C TT 21.3% (17/80) 30% (12/40) 24.5% (36/147)
TC 36.3% (29/80) 47.5% (19/40) 48.3% (71/147)
CC 42.5% (34/80) 22.5% (9/40) 27.2% (40/147)
c.*96A>G AA 100% (54/54) 100% (29/29) 99.2% (122/123)
AG 0% (0/54) 0% (0/29) 0.81% (1/123)
GG 0% (0/54) 0% (0/29) 0% (0/123)
c.*104A>T AA 57.7% (30/52) 79.3% (23/29) 68.1% (79/116)
AT 40.4% (21/52) 17.2% (5/29) 29.3% (34/116)
TT 1.9% (1/52) 3.4% (1/29) 2.6% (3/116)
c.*111C>T CC 57.1% (28/49) 79.3% (23/29) 67% (75/112)
CT 42.9% (21/49) 17.2% (5/29) 30.4% (34/112)
TT 0% (0/49) 3.4% (1/29) 2.7% (3/112)
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We have observed a statistically significant difference in the
distribution of genotypes regarding c.*84T>C between bilat-
eral HL patients and controls when considering only the cases
with severe and profound deafness (Table 3; p= 0.005). When
also including the moderate bilateral HL patients, the differ-
ence in genotypic distribution did not remain statistically
significant for the c.*84T>C variant ( p= 0.101).
GJB6 deletions
The del(GJB6-D13S1830) and del(GJB6-D13S1854)
GJB6 deletions have not been identified in the 134 patients
(90 bilateral +44 unilateral) or 177 controls analyzed.
Table 3. Genotypic Distribution Regarding
the c.*84T>C Variant in Controls and Patients
with Bilateral, Severe, or Profound Hearing
Loss (Chi-Square Test; p = 0.005)
c.*84T>C
TT TC CC Total
Controls 36 71 40 147
Expected count 38.4 61.3 47.3
Patients 16 12 24 52
Expected count 13.6 21.7 16.7
Total 52 83 64 199
Table 4. All GJB2 Variants Identified in This Study and the Populations, Per the 1000 Genomes
Project (Phase 3), in Which the Attendant Variants Have Been Observed
GJB2 variant dbSNP ID
Change at
protein level/
Location Effect
1000 genomes project
(phase 3) populationsa
c.-22-12C>T rs9578260 Intron Polymorphismb ACB, ASW, CLM, ESN, ITU, LWK, MSL,
MXL, PEL, PUR, YRI
c.-15C>T rs72561725 5¢UTR Polymorphismb ACB, ASW, CEU, CLM, ESN, GWD, LWK,
MSL, MXL, PUR, YRI
c.-14G>A rs367567291 5¢UTR Unknown n.a.
c.-7G>A rs398123813 5¢UTR Unknown n.a.
c.-6T>A rs148136545 5¢UTR Unknown ASW, CLM, ESN, LWK, MSL, PUR
c.35delG rs80338939 p.Gly12Valfs Pathogenicc BEB, CEU, CLM, FIN, GBR, IBS, MXL, TSI
c.101T>C rs35887622 p.Met34Thr Pathogenicd ASW, CEU, CLM, FIN, GBR, IBS, MXL,
PUR, TSI
c.109G>A rs72474224 p.Val37Ile Pathogenicc CDX, CHB, CHS, CLM, JPT, KHV,
LWK, MXL
c.186C>T rs397516869 p.Asn62 = Unknown n.a.
c.225G>T rs149137695 p.Arg75 = Unknown n.a.
c.380G>A rs111033196 p.Arg127His Controversial BEB, GBR, GIH, ITU, KHV, PJL, STU, TSI
c.457G>A rs111033186 p.Val153Ile Controversial BEB, CLM, GIH, ITU, PJL, STU, TSI
c.499G>A rs111033360 p.Val167Met Likely
pathogenice
LWK
c.*78A>T rs576671031 3¢UTR Unknown ACB
c.*84T>C rs3751385 3¢UTR Polymorphismf All populations
c.*96A>G rs188027627 3¢UTR Unknown ESN, LWK
c.*104A>T rs7337074 3¢UTR Polymorphismb ACB, ASW, CLM, ESN, GWD, IBS, LWK,
MSL, MXL, PEL, PUR, YRI
c.*111C>T rs7329857 3¢UTR Polymorphismb ACB, ASW, CLM, ESN, GIH, GWD, IBS,
LWK, MSL, MXL, PEL, PUR, YRI
Unknown—The authors consider that there are still insufficient data in the literature, including this study, for inferring benignity or
pathogenicity of the variant.
Controversial—In view of the conflicting data in the literature regarding the pathogenicity of the variant, the authors are unable to
classify it as either benign (polymorphism) or pathogenic.
aOne thousand Genome Project’s Populations: ACB, African Caribbeans in Barbados; ASW, Americans of African Ancestry in SW USA;
BEB, Bengali from Bangladesh; CDX, Chinese Dai in Xishuangbanna, China; CEU, Utah Residents (CEPH) with Northern and Western
European Ancestry; CHB, Han Chinese in Bejing, China; CHS, Southern Han Chinese; CLM, Colombians from Medelin, Colombia; ESN,
Esan in Nigera; FIN, Finnish in Finland; GBR, British in England and Scotland; GIH, Gujarati Indian from Houston, Texas; GWD, Gambian
in Western Divisions in The Gambia; IBS, Iberian population in Spain; ITU, Indian Telugu from the UK; JPT, Japanese in Tokyo, Japan;
KHV, Kinh in Ho Chi Minh City, Vietnam; LWK, Luhya in Webuye, Kenya; MSL, Mende in Sierra Leone; MXL, Mexican Ancestry from
Los Angeles USA; PEL, Peruvians from Lima, Peru; PJL, Punjabi from Lahore, Pakistan; PUR, Puerto Ricans from Puerto Rico; STU, Sri
Lankan Tamil from the UK; TSI, Toscani in Italy; YRI, Yoruba in Ibadan, Nigera.
bSignificant allelic frequencies in some 1000 Genome Project’s populations and homozygous genotypes have been observed in normal-
hearing controls.
cThe pathogenicity of the variant is well established in the literature.
dIn spite of OMIM considering this variant as one of unknown significance (www.omim.org/entry/121011), we considered it as path-
ogenic based on several reports from the literature.
eBased on in silico analytic tools as assessed at the Deafness Variation Database (http://deafnessvariationdatabase.org/).
fThis variant is clearly a polymorphism based on the genotypic frequencies available for several populations (dbSNP at NCBI).
n.a., not available.
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Discussion
HL remains an important global health burden. We high-
light and contextualize the salient findings and conclusions
from the present study.
Coding variants of GJB2
Pathogenic and controversial variants. In this study, with
regard to Sa˜o Tome´ and Prı´ncipe’s population, we have iden-
tified the pathogenic c.35delG, p.Met34Thr and p.Val37Ile
mutations, and the controversial p.Arg127His and p.Val153Ile
variants (Table 4). These five sequence changes are the most
commonly found in patients from Eurasian and Mediterranean
populations, and all have been previously found in Portuguese
HL patients (Matos et al., 2013). Thus, a non–Sub-Saharan
genetic influence in Sa˜o Tome´ and Prı´ncipe’s population is
suggested, and the European genetic influx reported by Toma´s
et al. (2002), most likely due to admixture with the Portuguese,
is supported by our results.
p.Val167Met: a likely recessive pathogenic variant. As
regards the p.Val167Met variant, it has been previously found,
in heterozygosity, in four Kenyans with prelingual, non-
syndromic HL (Gasmelseed et al., 2004) and in one Camer-
oonian HL patient (Bosch et al., 2014b). This variant has also
been observed in the Luhya (Webuye, Kenya) population
(Table 4), from the 1000 genomes project (www.1000genomes
.org/), in heterozygosity and with an allelic frequency of
0.51%. The p.Val167Met variant, carried by one control in-
dividual from our sample, was also present in 1 out of 188
African-American control chromosomes (Samanich et al.,
2007). The p.Val167Met variant has also been identified, in
heterozygosity, in two studies, including African-American
subjects, but the ethnicities of the carriers were not disclosed
(Putcha et al., 2007; Ross et al., 2007). In silico analytic tools,
as accessed at the Deafness Variation Database (http://
deafnessvariationdatabase.org/), suggest the pathogenicity of
p.Val167Met. Taking all together, p.Val167Met seems to be a
recessive pathogenic variant of Sub-Saharan African origin.
Synonymous variants. We have identified two synony-
mous variants as well. The p.Arg75 = variant was identified in
one bilateral HL patient and in five controls (5/177 al-
leles = 1.41%), and the p.Asn62 = variant was found in one
control individual (1/354 alleles = 0.28%). Noteworthy, these
two synonymous GJB2 coding variants, of as yet unknown
significance (Table 4), are present in Sub-Saharan African
and Eastern Asian populations (Bosch et al., 2014b; Chen
et al., 2014; Gasmelseed et al., 2004; Han et al., 2008; Ming-
kun et al., 2007; Trotta et al., 2011).
Noncoding variants of GJB2
As expected, the Sa˜o Tome´ and Prı´ncipe’s population
harbors someGJB2 noncoding variants that are shared mainly
with Sub-Saharan African populations and populations of a
Sub-Saharan African ancestry. A statistically significant dif-
ference in genotypic distribution regarding the c.*84T>C
variant was observed between controls and patients with
severe or profound bilateral HL ( p = 0.005).
The most common of the 10 noncoding variants genotyped
in the subjects of our sample, c.*84T>C, is also found in the
project’s populations of all the 1000 genomes (Table 4) and
was observed in the control sample with an allelic frequency
close to those of the Sub-Saharan populations as well as the
Americans of African ancestry, Han Chinese and Japanese
populations.
The c.*84T>C variant (rs3751385) has been previously
found to be significantly associated with HL (Dickson et al.,
2010), in the context of demonstrating the creation of synthetic
genome-wide associations by rare variants. In our sample, both
allele T and C at the c.*84 are common but a synthetic asso-
ciation between one or both c.*84 alleles and HL cannot be
excluded. A larger sample would be necessary to further in-
vestigate a putative association of variants at position c.*84
with HL in Sa˜o Tome´ and Prı´ncipe’s population.
As regards the noncoding variants c.-22-12C>T and
c.-15C>T, they were identified in controls with allelic fre-
quencies of 17.95% and 6.33%, respectively. These poly-
morphisms are the most frequent in Sub-Saharan African
populations and in populations of a Sub-Saharan African
ancestry (www.1000genomes.org/; Table 4).
The c.-6T>A variant, observed in controls with an allelic
frequency of 1.14%, is also the most frequent in Sub-Saharan
African populations and in populations of a Sub-Saharan
African ancestry (www.1000genomes.org/). To the extent of
our knowledge, this variant, of an unknown effect (Table 4),
has only been described in the heterozygous state (Al-
Qahtani et al., 2010; Shan et al., 2010; Tang et al., 2006;
www.1000genomes.org/).
Some other noncoding variants, of an unknown effect
(Table 4), were rarely observed in this study. The c.-7G>A,
c.-14G>A, c.*78A>T, and c.*96A>G variants were each ob-
served in our sample only once or twice, in heterozygosity.
The c.*96A>G variant was observed only in the Luhya (We-
buye, Kenya) and Essan (Nigeria) populations, in the hetero-
zygous form. The c.*78A>T variant has been observed only in
the African Caribbean (Barbados) population (Table 4), also in
the heterozygous form. No populational data are available for
the c.-7G>A and c.-14G>A variants (Table 4).
GJB6 deletions
None of the two large GJB6 deletions has been identified in
Sa˜o Tome´ and Prı´ncipe. These results are similar to those
obtained in previous studies on HL patients from Sub-
Saharan African populations and Sub-Saharan African
ancestry populations.
The del(GJB6-D13S1854) is not particularly frequent in
Portuguese NSSHL patients (0.4% of the patients’ alleles),
and the del(GJB6-D13S1830) seems to be fairly rare in these
patients (Chora et al., 2010; Matos et al., 2013). Given the
relatively low degree of European (mainly Portuguese) ad-
mixture of Sa˜o Tome´ and Prı´ncipe’s population (Toma´s et al.,
2002), it is likely that none of the GJB6 deletions plays a
relevant role in NSSHL in Sa˜o Tome´ and Prı´ncipe’s popu-
lation, as suggested by our data.
Conclusions
The role of GJB2 coding mutations in NSSHL in Sa˜o Tome´
and Prı´ncipe seems to be of little significance. Our study,
however, suggests the existence of pathogenic, and likely
pathogenic, coding variants in Sa˜o Tome´ and Prı´ncipe’s pop-
ulation. Thus, although no biallelic HL patients have been
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identified in our sample, the eventual occurrence of GJB2-
related HL in this population should not be disregarded. The
role of the GJB6 large deletions in NSSHL in Sa˜o Tome´ and
Prı´ncipe, if any, is predicted by this study to be small.
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